Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHL018
MIFTS: 50

Childhood Medulloblastoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Childhood Medulloblastoma

About this section

MalaCards integrated aliases for Childhood Medulloblastoma:

Name: Childhood Medulloblastoma 12 54 15
Medulloblastoma, Childhood 54 74
Pediatric Medulloblastoma 12
Medulloblastoma Childhood 56

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3869
MeSH 45 D008527
NCIt 51 C3997
UMLS 74 C0278510
Sources

Summaries for Childhood Medulloblastoma

About this section
MalaCards based summary : Childhood Medulloblastoma, also known as medulloblastoma, childhood, is related to basal cell nevus syndrome and basal cell carcinoma, and has symptoms including vomiting, gait ataxia and headache. An important gene associated with Childhood Medulloblastoma is CRNDE (Colorectal Neoplasia Differentially Expressed), and among its related pathways/superpathways are Pathways in cancer and Apoptosis Pathway. The drugs Vincristine and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow, and related phenotypes are behavior/neurological and cardiovascular system

Sources

Related Diseases for Childhood Medulloblastoma

About this section

Diseases related to Childhood Medulloblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
# Related Disease Score Top Affiliating Genes
1 basal cell nevus syndrome 29.3 GLI2 PTCH1 SUFU
2 basal cell carcinoma 29.3 GLI2 PTCH1 SUFU
3 medulloblastoma 29.0 DDX3X ERBB3 ERBB4 GLI2 MYC MYCN
4 vulva basal cell carcinoma 10.3 MYC PTCH1
5 askin's tumor 10.3 MYC MYCN
6 bone ewing's sarcoma 10.2 MYC MYCN
7 cerebral primitive neuroectodermal tumor 10.2 MYC MYCN
8 medullomyoblastoma 10.2 MYC MYCN
9 nervous system cancer 10.1 MYC MYCN PTCH1
10 cerebellar liponeurocytoma 10.1 PTCH1 SUFU
11 adult medulloblastoma 10.0 MYCN PTCH1 SUFU
12 keratocystic odontogenic tumor 10.0 PTCH1 SUFU
13 holoprosencephaly, recurrent infections, and monocytosis 10.0 GLI2 PTCH1
14 calcifying epithelial odontogenic tumor 10.0 GLI2 PTCH1
15 septopreoptic holoprosencephaly 10.0 GLI2 PTCH1
16 ewing's family of tumors 10.0
17 midline interhemispheric variant of holoprosencephaly 10.0 GLI2 PTCH1
18 alobar holoprosencephaly 9.9 GLI2 PTCH1
19 lobar holoprosencephaly 9.9 GLI2 PTCH1
20 semilobar holoprosencephaly 9.9 GLI2 PTCH1
21 brain cancer 9.9 MYC MYCN NTRK3 PTCH1
22 greig cephalopolysyndactyly syndrome 9.9 GLI2 PTCH1
23 central nervous system cancer 9.9 MYC MYCN PTCH1 SUFU
24 adenocarcinoma 9.8 ERBB3 ERBB4 MYC NTRK3
25 aging 9.8
26 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
27 hepatic veno-occlusive disease 9.8
28 hypothyroidism 9.8
29 atypical teratoid rhabdoid tumor 9.8
30 rhabdoid cancer 9.8
31 benign ependymoma 9.8
32 ependymoma 9.8
33 radiation induced cancer 9.8
34 basal cell carcinoma 1 9.8
35 pineoblastoma, childhood 9.8
36 herpes simplex 9.8
37 congenital hydrocephalus 9.8
38 cytomegalovirus infection 9.8
39 hydrocephalus 9.8
40 alopecia 9.8
41 esophageal atresia 9.7 GLI2 MYCN
42 nodular medulloblastoma 9.7 GLI2 PTCH1 SUFU
43 microform holoprosencephaly 9.7 GLI2 PTCH1 SUFU
44 bardet-biedl syndrome 17 9.6 GLI2 PTCH1
45 infratentorial cancer 9.2 GLI2 MYC MYCN NTRK3 PTCH1 SUFU

Graphical network of the top 20 diseases related to Childhood Medulloblastoma:



Diseases related to Childhood Medulloblastoma
Sources

Symptoms & Phenotypes for Childhood Medulloblastoma

About this section

UMLS symptoms related to Childhood Medulloblastoma:


vomiting, gait ataxia, headache

MGI Mouse Phenotypes related to Childhood Medulloblastoma:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 ERBB3 ERBB4 GLI2 MYC MYCN NTRK3
2 cardiovascular system MP:0005385 10.15 DDX3X ERBB3 ERBB4 MYC MYCN NTRK3
3 growth/size/body region MP:0005378 10.15 DDX3X ERBB3 GLI2 MYC MYCN NTRK3
4 mortality/aging MP:0010768 10.13 DDX3X ERBB3 ERBB4 GLI2 MYC MYCN
5 embryo MP:0005380 10.11 DDX3X ERBB3 ERBB4 GLI2 MYC MYCN
6 nervous system MP:0003631 10.07 DDX3X ERBB3 ERBB4 GLI2 MYC MYCN
7 craniofacial MP:0005382 10.01 ERBB4 GLI2 MYC MYCN PTCH1 SUFU
8 digestive/alimentary MP:0005381 10 ERBB3 GLI2 MYC MYCN PTCH1 SUFU
9 normal MP:0002873 9.96 DDX3X ERBB3 ERBB4 GLI2 MYC MYCN
10 integument MP:0010771 9.95 ERBB3 ERBB4 GLI2 MYC PTCH1 SUFU
11 muscle MP:0005369 9.95 DDX3X ERBB3 ERBB4 GLI2 MYC MYCN
12 limbs/digits/tail MP:0005371 9.85 GLI2 MYC MYCN PTCH1 SUFU
13 no phenotypic analysis MP:0003012 9.8 GLI2 MYC MYCN NTRK3 PTCH1 SUFU
14 pigmentation MP:0001186 9.46 ERBB3 MYC PTCH1 SUFU
15 reproductive system MP:0005389 9.43 ERBB4 GLI2 MYC MYCN NTRK3 PTCH1
16 respiratory system MP:0005388 9.23 ERBB3 ERBB4 GLI2 MYCN NTRK3 PTCH1
Sources

Drugs & Therapeutics for Childhood Medulloblastoma

About this section

Drugs for Childhood Medulloblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 234)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
2
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
4
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
5
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
6
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
7
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
8
leucovorin Approved Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
10
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2 85622-93-1 5394
11
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
12
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
13
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
14
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1 3375-50-6 598
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
19
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5282379 5538
20
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6 774
21
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-30-3 6037
23
Calcium Approved, Nutraceutical Phase 3,Phase 2 7440-70-2 271
24
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 444795 5538
25
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3,Phase 1 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
26
Emodepside Investigational, Vet_approved Phase 3,Phase 2,Phase 1 155030-63-0
27 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
29 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
30 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
32 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
33 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Not Applicable
35 Vitamin B9 Phase 3,Phase 2,Not Applicable
36 Folate Phase 3,Phase 2,Not Applicable
37 Folic Acid Antagonists Phase 3,Phase 2,Not Applicable
38 Antimetabolites Phase 3,Phase 2,Not Applicable
39 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
40 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
41 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
42 Vitamin B Complex Phase 3,Phase 2,Not Applicable
43 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
45 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Hormones Phase 3,Phase 2,Phase 1
47 Trace Elements Phase 3,Phase 2
48 Calcium, Dietary Phase 3,Phase 2
49 Vitamins Phase 3,Phase 1
50 Antidotes Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 133)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
2 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Unknown status NCT01987596 Phase 3
3 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
4 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Completed NCT00085735 Phase 3 Cisplatin;Cyclophosphamide;Lomustine;Vincristine Sulfate
5 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Completed NCT00336024 Phase 3 etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate
6 Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor Completed NCT00006461 Phase 3 cisplatin;cyclophosphamide;vincristine sulfate;etoposide
7 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Completed NCT00002875 Phase 3 cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate
8 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
9 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
10 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
11 Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma Suspended NCT00392327 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Isotretinoin;Vincristine Sulfate
12 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
13 Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery Unknown status NCT00276666 Phase 2 cisplatin;lomustine;vincristine sulfate
14 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
15 Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma Completed NCT01239316 Phase 2 Vismodegib
16 Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma Completed NCT00003573 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
17 Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor Completed NCT00003211 Phase 2 amifostine trihydrate;cisplatin;cyclophosphamide;vincristine sulfate
18 Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors Completed NCT00025077 Phase 2 carboplatin;cyclophosphamide;thiotepa
19 Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors Completed NCT00002594 Phase 2 cyclophosphamide;melphalan
20 Ga-DOTATOC Versus Octreoscan + CT Completed NCT01869725 Phase 2
21 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2 Oxaliplatin
22 Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors Completed NCT00003203 Phase 2 carboplatin;cisplatin;cyclophosphamide;vincristine sulfate
23 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
24 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
25 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
26 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
27 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
28 Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment Completed NCT00005811 Phase 2 topotecan hydrochloride
29 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
30 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
31 Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors Completed NCT00003846 Phase 2 carboplatin;cyclophosphamide;thiotepa;vincristine sulfate
32 Lobradimil and Carboplatin in Treating Children With Brain Tumors Completed NCT00019422 Phase 2 carboplatin;lobradimil
33 Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00003241 Phase 2 phenylacetate
34 Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
35 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
36 Docetaxel in Treating Children With Recurrent Solid Tumors Completed NCT00002825 Phase 2 docetaxel
37 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
38 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
39 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
40 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
41 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
42 Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Recruiting NCT02724579 Phase 2 Cisplatin;Cyclophosphamide;Lomustine;Vincristine Sulfate
43 Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors Recruiting NCT02684071 Phase 2 Intra thecal methotrexate;topotecan;cyclophosphamide
44 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting NCT03213704 Phase 2 Larotrectinib;Larotrectinib Sulfate
45 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03210714 Phase 2 Erdafitinib
46 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
47 A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Recruiting NCT01878617 Phase 2 Cyclophosphamide;Cisplatin;Vincristine;Vismodegib;Pemetrexed;Gemcitabine
48 Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Recruiting NCT02624388 Phase 2 Genistein;Placebo
49 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Active, not recruiting NCT01217437 Phase 2 Irinotecan Hydrochloride;Temozolomide
50 Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma Active, not recruiting NCT02017964 Phase 2 Carboplatin;Cyclophosphamide;Etoposide;Methotrexate;Vincristine Sulfate

Search NIH Clinical Center for Childhood Medulloblastoma

Sources

Genetic Tests for Childhood Medulloblastoma

About this section
Sources

Anatomical Context for Childhood Medulloblastoma

About this section

MalaCards organs/tissues related to Childhood Medulloblastoma:

42
Brain, Bone, Bone Marrow, Testes, Spinal Cord, Liver, T Cells
Sources

Publications for Childhood Medulloblastoma

About this section

Articles related to Childhood Medulloblastoma:

(show top 50) (show all 131)
# Title Authors Year
1
Twenty years experience in treating childhood medulloblastoma: Between the past and the present. ( 31109839 )
2019
2
Intellectual, educational, and situation-based social outcome in adult survivors of childhood medulloblastoma. ( 29336639 )
2019
3
Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. ( 29189165 )
2018
4
Neuropsychological consequences of childhood medulloblastoma and possible interventions: A review. ( 29716738 )
2018
5
National cancer registry and broad institutional cooperation: turning points in treating childhood medulloblastoma in Iran. ( 29804211 )
2018
6
Study on Contribution of Biological Interpretable and Computer-Aided Features Towards the Classification of Childhood Medulloblastoma Cells. ( 29974336 )
2018
7
Childhood Medulloblastoma Revisited. ( 30516696 )
2018
8
Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. ( 27900530 )
2017
9
The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. ( 27785591 )
2017
10
Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns. ( 27770281 )
2017
11
Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. ( 28039368 )
2017
12
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. ( 28545823 )
2017
13
Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia. ( 28717752 )
2017
14
Childhood medulloblastoma. ( 27375228 )
2016
15
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. ( 27040285 )
2016
16
Evolving molecular era of childhood medulloblastoma: time to revisit therapy. ( 26617331 )
2016
17
CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastoma. ( 26290144 )
2015
18
The use of 5-ALA to assist complete removal of residual non-enhancing part of childhood medulloblastoma: a case report. ( 26070965 )
2015
19
Evidence of high mortality in long term survivors of childhood medulloblastoma. ( 25557108 )
2015
20
Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue. ( 25346052 )
2015
21
Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. ( 25403219 )
2014
22
The biologic era of childhood medulloblastoma and clues to novel therapies. ( 24754593 )
2014
23
NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. ( 24708907 )
2014
24
Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. ( 24569911 )
2014
25
Hepatic sinusoidal obstruction syndrome during chemotherapy for childhood medulloblastoma: report of a case and review of the literature. ( 24276042 )
2014
26
Treatment options for childhood medulloblastoma. ( 24069828 )
2013
27
miR-218 is downregulated and directly targets SH3GL1 in childhood medulloblastoma. ( 23970061 )
2013
28
A contemporary review of molecular candidates for the development and treatment of childhood medulloblastoma. ( 23292496 )
2013
29
Cerebral white matter integrity and executive function in adult survivors of childhood medulloblastoma. ( 23095827 )
2012
30
Maternal variation in EPHX1, a xenobiotic metabolism gene, is associated with childhood medulloblastoma: an exploratory case-parent triad study. ( 22994552 )
2012
31
Chemotherapy dose-intensity and survival for childhood medulloblastoma. ( 22993333 )
2012
32
Identification of suitable endogenous control genes for microRNA expression profiling of childhood medulloblastoma and human neural stem cells. ( 22980291 )
2012
33
Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile. ( 22826514 )
2012
34
An exploratory case-only analysis of gene-hazardous air pollutant interactions and the risk of childhood medulloblastoma. ( 22389292 )
2012
35
Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma. ( 22350379 )
2012
36
A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma. ( 22153558 )
2012
37
MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. ( 22139329 )
2012
38
Low-grade bone lesions in survivors of childhood medulloblastoma/primitive neuroectodermal tumor. ( 22054800 )
2012
39
Early traits of metabolic syndrome in pediatric post-cancer survivors: outcomes in adolescents and young adults treated for childhood medulloblastoma. ( 22218450 )
2011
40
Integrated analysis of miRNA and mRNA expression in childhood medulloblastoma compared with neural stem cells. ( 21931624 )
2011
41
Progress in sequencing human cancer genomes: advancements in childhood medulloblastoma. ( 21900800 )
2011
42
Risk-adapted chemotherapy in childhood medulloblastoma. ( 21554052 )
2011
43
Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes. ( 21367970 )
2011
44
Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. ( 21317922 )
2011
45
Intact language skills and semantic processing speed following the use of fractionated cranial irradiation therapy for the treatment of childhood medulloblastoma: a 4-year follow-up study. ( 21207315 )
2011
46
Childhood medulloblastoma. ( 21129995 )
2011
47
Recurrence in childhood medulloblastoma. ( 21069427 )
2011
48
Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. ( 20931205 )
2011
49
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. ( 20921458 )
2011
50
Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. ( 20845476 )
2011
Sources

Variations for Childhood Medulloblastoma

About this section
Sources

Expression for Childhood Medulloblastoma

About this section
Search GEO for disease gene expression data for Childhood Medulloblastoma.
Sources

Pathways for Childhood Medulloblastoma

About this section

Pathways related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 38
12.46 GLI2 MYC PTCH1 SUFU
2
Apoptosis Pathway 73
Show member pathways
 12.11 ERBB3 ERBB4 NTRK3
3
Wnt Signaling Pathways: beta-Catenin-dependent Wnt Signaling 66
Show member pathways
 12.07 GLI2 PTCH1 SUFU
4
Wnt / Hedgehog / Notch 4
11.89 GLI2 PTCH1 SUFU
5
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 11.81 ERBB3 ERBB4 MYC NTRK3
6
Proteoglycans in cancer 38
11.76 ERBB3 ERBB4 MYC PTCH1
7
Hedgehog Pathway 73
Show member pathways
 11.65 GLI2 PTCH1 SUFU
8
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 23
11.09 GLI2 PTCH1
9
G-protein signaling_Cross-talk between Ras-family GTPases 23
11.08 ERBB3 ERBB4 NTRK3
10
AKT Signaling Pathway 68
11.08 ERBB3 ERBB4 MYC NTRK3
11
Signaling events mediated by the Hedgehog family 1
Show member pathways
 11 GLI2 PTCH1
12
Alzheimers Disease Pathway 65
10.79 ERBB3 ERBB4 NTRK3
13
Notch Pathway 73
9.96 MYC MYCN
Sources

GO Terms for Childhood Medulloblastoma

About this section

Cellular components related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ciliary tip GO:0097542 9.26 GLI2 SUFU
2 ciliary base GO:0097546 9.16 GLI2 SUFU
3 basal plasma membrane GO:0009925 8.96 ERBB3 ERBB4
4 receptor complex GO:0043235 8.8 ERBB3 ERBB4 NTRK3

Biological processes related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.9 ERBB4 GLI2 MYC NTRK3
2 positive regulation of transcription, DNA-templated GO:0045893 9.85 ERBB4 GLI2 MYC MYCN PTCH1
3 MAPK cascade GO:0000165 9.81 ERBB3 ERBB4 MYC
4 in utero embryonic development GO:0001701 9.79 GLI2 MYC PTCH1
5 peptidyl-tyrosine phosphorylation GO:0018108 9.77 ERBB3 ERBB4 NTRK3
6 heart development GO:0007507 9.71 ERBB3 ERBB4 GLI2 NTRK3
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.69 ERBB3 ERBB4 NTRK3
8 branching involved in ureteric bud morphogenesis GO:0001658 9.65 MYC PTCH1
9 dorsal/ventral pattern formation GO:0009953 9.65 GLI2 PTCH1
10 regulation of mitotic cell cycle GO:0007346 9.64 MYC PTCH1
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.64 ERBB4 NTRK3
12 liver regeneration GO:0097421 9.63 MYC PTCH1
13 mammary gland development GO:0030879 9.62 GLI2 PTCH1
14 ERBB2 signaling pathway GO:0038128 9.61 ERBB3 ERBB4
15 regulation of cell motility GO:2000145 9.61 ERBB3 ERBB4
16 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.61 ERBB3 ERBB4 NTRK3
17 negative regulation of smoothened signaling pathway GO:0045879 9.58 PTCH1 SUFU
18 regulation of smoothened signaling pathway GO:0008589 9.58 GLI2 PTCH1
19 spinal cord motor neuron differentiation GO:0021522 9.57 GLI2 PTCH1
20 dorsal/ventral neural tube patterning GO:0021904 9.55 GLI2 PTCH1
21 mammary gland epithelial cell differentiation GO:0060644 9.52 ERBB4 PTCH1
22 negative regulation of cell division GO:0051782 9.49 MYC PTCH1
23 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.48 GLI2 PTCH1
24 mammary gland duct morphogenesis GO:0060603 9.37 GLI2 PTCH1
25 positive regulation of gene expression GO:0010628 9.35 DDX3X ERBB3 MYC MYCN NTRK3
26 spinal cord dorsal/ventral patterning GO:0021513 9.32 GLI2 SUFU
27 positive regulation of MAPK cascade GO:0043410 9.26 NTRK3
28 smoothened signaling pathway involved in spinal cord motor neuron cell fate specification GO:0021776 9.26 GLI2 SUFU
29 negative regulation of signal transduction GO:0009968 9.24 ERBB3
30 smoothened signaling pathway involved in ventral spinal cord interneuron specification GO:0021775 9.16 GLI2 SUFU
31 negative regulation of apoptotic process GO:0043066 8.8 MYC GLI2 DDX3X

Molecular functions related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.33 ERBB3 ERBB4 NTRK3
2 transcription factor binding GO:0008134 9.26 DDX3X GLI2 MYC SUFU
3 transmembrane signaling receptor activity GO:0004888 8.96 ERBB3
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 ERBB3 ERBB4 NTRK3
Sources

Sources for Childhood Medulloblastoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....